Literature DB >> 6302245

A rapid and simple method for the quantitative determination of tolerance development to opiates in the guinea-pig ileum in vitro.

A Rezvani, J P Huidobro-Toro, J Hu, E L Way.   

Abstract

The rate and degree of tolerance development of morphine, normorphine and methadone were assessed in vitro on the guinea-pig ileum. After the half-maximal concentration to inhibit electrically induced contractions (IC50) for each compound was determined, tolerance to a fixed concentration representing 0.5, 1 or 2 times its IC50 was induced by incubation at 37 degrees C for 1, 2 or 4 hr. The IC50 was then redetermined and the ratio of the IC50 after and before incubation provided a quantitative index of the degree of tolerance development to each agonist. For any given concentration or time, morphine induced the highest, whereas normorphine the intermediate and methadone the lowest degree of tolerance. Tolerance to opiates was associated with some degree of physical dependence as evidenced by the fact that the application of naloxone at the end of each experiment elicited a muscular contraction. Specificity of tolerance development to opiates was demonstrated by several experiments. Coincubation of morphine with naloxone under the same conditions resulted in an inhibition of tolerance development. The stereospecificity of the process was demonstrated by the fact that levorphanol and I-methadone induced a high degree of tolerance, whereas, under the same conditions the less active d-isomers, dextrorphan and d-methadone, did not. Moreover, subsensitivity to acetylcholine, norepinephrine and adenosine monophosphate did not develop in the presence of tolerance to morphine. The validity of this method for investigating mechanisms involved in tolerance and physical dependence was further demonstrated by obtaining data compatible with earlier experiments in vivo that cyclic AMP enhances tolerance development and cycloheximide inhibits this phenomenon. The present method should facilitate studies on the mechanisms involved in opiate tolerance and physical dependence development.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6302245

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Site and mechanism of morphine tolerance in the gastrointestinal tract.

Authors:  H I Akbarali; A Inkisar; W L Dewey
Journal:  Neurogastroenterol Motil       Date:  2014-10       Impact factor: 3.598

2.  FK506-binding protein 12 modulates μ-opioid receptor phosphorylation and protein kinase C(ε)-dependent signaling by its direct interaction with the receptor.

Authors:  Yu Qiu; Wei Zhao; Yan Wang; Jian-Rong Xu; Eddie Huie; Shan Jiang; Ying-Hui Yan; Horace H Loh; Hong-Zhuan Chen; Ping-Yee Law
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

3.  The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract.

Authors:  Minho Kang; Hercules T Maguma; Tricia H Smith; Gracious R Ross; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2011-11-30       Impact factor: 4.030

4.  Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375.

Authors:  Stefan Schulz; Dana Mayer; Manuela Pfeiffer; Ralf Stumm; Thomas Koch; Volker Höllt
Journal:  EMBO J       Date:  2004-07-22       Impact factor: 11.598

5.  Morphine tolerance in the mouse ileum and colon.

Authors:  Gracious R Ross; Bichoy H Gabra; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2008-08-05       Impact factor: 4.030

6.  Critical interactions between opioid and cannabinoid receptors during tolerance and physical dependence development to opioids in the murine gastrointestinal tract: proof of concept.

Authors:  Agata Szymaszkiewicz; Mikołaj Świerczyński; Marcin Talar; Prabhakar Reddy Polepally; Jordan K Zjawiony; Jakub Fichna; Marta Zielińska
Journal:  Pharmacol Rep       Date:  2021-06-16       Impact factor: 3.024

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.